Retrospective Study
Copyright ©The Author(s) 2019.
World J Clin Oncol. Feb 24, 2019; 10(2): 86-97
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.86
Table 4 Multivariable analysis shows no association of cell doses with overall survival or progression free survival, except for total nucleated cell dose in the reduced intensity conditioning + total body irradiation group
VariableOverall survival1
Progression free survival2
All patients (n = 247)MA-noTBI (n = 38)MA + TBI (n = 51)RIC-noTBI (n = 118)RIC + TBI (n = 40)All patients (n = 247)MA-noTBI (n = 38)MA + TBI (n = 51)RIC-noTBI (n = 118)RIC + TBI (n = 40)
CD3+ cell dose
< Median HR1111111111
> Median HR1.11.00.51.30.81.01.10.41.40.6
95%CI0.8-1.50.4-2.60.2-1.10.8-2.10.3-2.20.7-1.40.4-2.60.2-1.00.8-2.20.2-1.7
PNSNSNSNSNSNSNS0.05NSNS
CD4+ cell dose
< Median HR1111111111
> Median HR1.21.10.61.22.01.11.10.50.31.5
95%CI0.8-1.70.4-2.60.2-1.30.8-1.00.7-6.00.8-1.60.5-2.60.2-1.20.8-2.10.5-4.3
PNSNSNSNSNSNSNSNSNSNS
CD8+ cell dose
< Median HR1111111111
> Median HR1.21.51.01.30.51.11.10.91.20.7
95%CI0.8-1.60.5-4.20.4-2.30.8-2.10.2-1.80.8-1.50.5-2.80.4-2.00.8-2.00.2-2.0
PNSNSNSNSNSNSNSNSNSNS
TNC dose
< Median HR1111111111
> Median HR0.81.00.70.90.20.81.10.71.10.2
95%CI0.6-1.20.4-2.40.3-1.90.5-1.50.1-0.80.6-1.20.4-2.50.3-1.60.6-1.80.1-0.8
PNSNSNSNS0.02NSNSNSNS0.02
CD34+ cell dose
< 4 × 106/kg HR1111111111
4-8 × 106/kg HR1.00.51.31.10.60.80.71.21.00.6
95%CI0.6-1.50.2-1.40.4-4.40.6-1.90.1-2.30.6-1.40.2-2.10.4-4.00.6-1.80.2-2.6
PNSNSNSNSNSNSNSNSNSNS
> 8 × 106/kg HR1.01.30.71.10.50.91.50.61.10.5
95%CI0.6-1.50.4-4.00.2-2.30.5-2.00.1-2.40.6-1.40.5-4.60.2-2.00.6-2.00.1-2.6
PNSNSNSNSNSNSNSNSNSNS